{"id":49464,"date":"2022-10-11T10:01:37","date_gmt":"2022-10-11T08:01:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/"},"modified":"2022-10-11T10:01:37","modified_gmt":"2022-10-11T08:01:37","slug":"tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/","title":{"rendered":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer"},"content":{"rendered":"
\n

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318<\/a>), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication.\n<\/p>\n

<\/a><\/p>\n

\nThis open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with MSD\u2019s (a tradename of Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy, KEYTRUDA\u00ae <\/sup>(pembrolizumab), is for platinum resistant or refractory ovarian cancer (PROTA, also called TILT-T563). The US patient, treated at the Mayo Clinic, should complete enrollment in the first cohort of three patients, the other two located in Finland. The Phase I trial is expected to enroll up to 15 patients.\n<\/p>\n

\nThe company\u2019s European and US open phase I clinical programs now cover several cancer types including ovarian cancer, head and neck cancer, and melanoma. In September, the company announced a new collaboration and supply agreement with MSD to evaluate TILT-123 in combination with KEYTRUDA in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.\n<\/p>\n

\nTILT Biotherapeutics\u2019 CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with earlier versions of oncolytic viruses, said, \u201cOvarian cancer is a killer disease with a pressing need for better therapies. There are no oncolytic viruses or check point inhibitors approved for use in that indication. The first US patient dosed is a significant milestone as we strive to make a difference using our armed oncolytic viruses in this difficult to treat disease. It\u2019s a pleasure to work with the prestigious Mayo Clinic to deliver such innovation with impact<\/a>. We are investing in our own US operations and opening US trial sites by the end of the year, as we advance towards Phase 2 trials.\u201d\n<\/p>\n

\nThe heart of TILT\u2019s innovative approach revolves around the use of cancer cell specific oncolytic adenoviruses, armed with cytokines and other molecules to boost the patient\u2019s T-cell immune response to better enable it to find and destroy cancer cells.\n<\/p>\n

\n-Ends-\n<\/p>\n

\nKEYTRUDA\u00ae is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.\n<\/p>\n

\nAbout TILT Biotherapeutics<\/b>\n<\/p>\n

\nTILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company\u2019s patented TILT\u00ae<\/sup> technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies.\n<\/p>\n

\nTILT\u2019s lead asset, TILT-123, is a 5\/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo<\/i>, and it is currently in Phase I clinical trials.\n<\/p>\n

\nThe Company\u2019s pioneering approach has been recognized by industry leaders including with the Merck KGaA and Pfizer Alliance, who are collaborating to investigate TILT-123\u2019s therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio\u00ae<\/sup>), in Head and Neck cancer (NCT05222932). The Company has two collaborations with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, investigating TILT-123 in combination with pembrolizumab (KEYTRUDA\u00ae<\/sup>) in Ovarian Cancer (NCT05271318) and in refractory non-small cell lung cancer. In 2019, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of TILT\u2019s proprietary oncolytic virus TILT-123 in Greater China.\n<\/p>\n

\nBased in Helsinki, Finland, the company was established in 2013 as a spin-out from the University of Helsinki. It has funding from Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, and the European Innovation Council.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contacts<\/b>
TILT Biotherapeutics<\/b>
CBO Aino Kalervo
\n
aino@tiltbio.com<\/a><\/p>\n

Scius Communications<\/b>
Katja Stout
\n
+447789435990
\n
katja@sciuscommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication. This open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49464","6":"format-standard","7":"category-industry"},"yoast_head":"\nTILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication. This open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T08:01:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer\",\"datePublished\":\"2022-10-11T08:01:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/\"},\"wordCount\":653,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005070\\\/en\\\/1595780\\\/21\\\/Tilt-final-logo-Blu-600.239-300x131.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/\",\"name\":\"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005070\\\/en\\\/1595780\\\/21\\\/Tilt-final-logo-Blu-600.239-300x131.jpg\",\"datePublished\":\"2022-10-11T08:01:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005070\\\/en\\\/1595780\\\/21\\\/Tilt-final-logo-Blu-600.239-300x131.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011005070\\\/en\\\/1595780\\\/21\\\/Tilt-final-logo-Blu-600.239-300x131.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend","og_description":"HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indication. This open-label, phase I, dose-escalation, multicenter, and multinational, clinical trial of TILT-123 in combination with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T08:01:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer","datePublished":"2022-10-11T08:01:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/"},"wordCount":653,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/","url":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/","name":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg","datePublished":"2022-10-11T08:01:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011005070\/en\/1595780\/21\/Tilt-final-logo-Blu-600.239-300x131.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tilt-biotherapeutics-announces-first-us-patient-dosed-in-immunotherapy-clinical-trial-in-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49464"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49464\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}